Compare HROW & ATEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HROW | ATEC |
|---|---|---|
| Founded | 1998 | 1990 |
| Country | United States | United States |
| Employees | 373 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | N/A | 2006 |
| Metric | HROW | ATEC |
|---|---|---|
| Price | $46.15 | $9.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $69.86 | $22.00 |
| AVG Volume (30 Days) | 853.2K | ★ 3.3M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $101,739,000.00 |
| Revenue This Year | $31.62 | $18.97 |
| Revenue Next Year | $50.77 | $16.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.54 | $6.82 |
| 52 Week High | $54.98 | $23.29 |
| Indicator | HROW | ATEC |
|---|---|---|
| Relative Strength Index (RSI) | 70.69 | 61.93 |
| Support Level | $44.30 | $7.05 |
| Resistance Level | $51.01 | $9.57 |
| Average True Range (ATR) | 2.20 | 0.54 |
| MACD | 0.36 | 0.11 |
| Stochastic Oscillator | 91.44 | 91.13 |
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.